Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Related topics
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Nov 14, 2023
The xCELLigence RTCA eSight enables simultaneous real time biosensor impedance-based and...
NanoCellect webinar: Plant Potential - Gentle Cell Sorting for Enhanced Plant Biology Workflows
Nov 3, 2023
Gentle cell sorting is a useful tool to increase the efficiency of plant biology workflows that include gene...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Nov 2, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
Oct 31, 2023
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Oct 30, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Related technologies: PET, SPECT, CT
Get more info
Brand profile
Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
More info at:
www.bruker.com